Glax­o­SmithK­line dou­bles down on Cure­Vac's mR­NA tech, bets $180M on the hunt for next-gen vac­cine

As new vari­ants high­light the pos­si­bil­i­ty that we will have to live with Covid-19 for­ev­er, Glax­o­SmithK­line is dou­bling down on its Cure­Vac part­ner­ship in search of an mR­NA vac­cine of the fu­ture.

And if it all goes smooth­ly, GSK might have a block­buster vac­cine all of its own in 2022.

Bankrolled with $180 mil­lion (€150 mil­lion) from GSK, the new co-de­vel­op­ment pact will see both com­pa­nies con­tribut­ing re­sources and ex­per­tise to­ward a num­ber of new mR­NA vac­cine can­di­dates — “in­clud­ing mul­ti-va­lent and mono­va­lent ap­proach­es.” €75 mil­lion of that is paid up­front and the rest is in mile­stones.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER